EPIDEMIOLOGY OF COMPLICATION DEVELOPMENT IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
- Authors
-
-
Mirzarakhimova Nasiba
Doctorate 2nd issue Department of Public Health and Healthcare Management Tashkent State Medical University
Author
-
- Keywords:
- Type 2 diabetes mellitus; epidemiology; diabetic complications; cardiovascular disease; microvascular complications; disease burden
- Abstract
-
Type 2 diabetes mellitus represents a major global public health burden due to its rapidly increasing prevalence and strong association with a wide spectrum of chronic complications. This study aims to analyze the epidemiological patterns of complication development in patients with type 2 diabetes mellitus, with particular emphasis on cardiovascular, cerebrovascular, renal, and metabolic outcomes. The analysis is based on population-based epidemiological data, clinical registries, and observational studies evaluating the incidence, prevalence, and risk factors of diabetes-related complications. The findings demonstrate that the risk of both macrovascular and microvascular complications increases significantly with disease duration, poor glycemic control, and the presence of concomitant metabolic disorders. Cardiovascular complications remain the leading cause of morbidity and mortality among patients with type 2 diabetes, while diabetic nephropathy and neuropathy represent major contributors to long-term disability. The epidemiological evidence indicates that complications often develop subclinically and progress over time, underscoring the importance of early detection and continuous surveillance. These results highlight the critical role of epidemiological assessment in understanding complication dynamics and support the implementation of population-based prevention strategies to reduce the burden of type 2 diabetes mellitus and its complications.
- References
-
1.American Diabetes Association. (2023). Standards of medical care in diabetes—2023. Diabetes Care, 46(Suppl. 1), S1–S291. https://doi.org/10.2337/dc23-SINT
2.Gregg, E. W., Li, Y., Wang, J., et al. (2014). Changes in diabetes-related complications in the United States. New England Journal of Medicine, 370(16), 1514–1523. https://doi.org/10.1056/NEJMoa1310799
3.Rawshani, A., Rawshani, A., Franzén, S., et al. (2018). Mortality and cardiovascular disease in type 2 diabetes. New England Journal of Medicine, 379(7), 633–644. https://doi.org/10.1056/NEJMoa1800256
4.Sarwar, N., Gao, P., Seshasai, S. R. K., et al. (2010). Diabetes mellitus, fasting blood glucose, and risk of vascular disease. The Lancet, 375(9733), 2215–2222. https://doi.org/10.1016/S0140-6736(10)60484-9
5.Stratton, I. M., Adler, A. I., Neil, H. A. W., et al. (2000). Association of glycaemia with complications of type 2 diabetes. BMJ, 321(7258), 405–412. https://doi.org/10.1136/bmj.321.7258.405
6.Tesfaye, S., Boulton, A. J. M., Dyck, P. J., et al. (2010). Diabetic neuropathies. Diabetes Care, 33(10), 2285–2293. https://doi.org/10.2337/dc10-1303
7.Ташпулатова, Ф. К., Садыков, А. С., & Галиуллин, Т. И. (2017). МЕДИКО-СОЦИАЛЬНЫЕ АСПЕКТЫ ТУБЕРКУЛЕЗА ЛЕГКИХ И ВИЧ. Фтизиатрия и пульмонология, (2), 136-136.
8.Bekembayeva, G. S., & Tashpulatova, F. K. (2021). PROGNOSIS OF RESISTANT TUBERCULOSIS COURSE AMONG CHILDREN AND TEENAGERS. Новый день в медицине, (1), 48-51.
9.Khomova, N., Tashpulatova, F., & Sultanov, S. (2017). Compliance-is patient adherence to treatment, as well as partnerships between doctor and patient.
10.Ташпулатова, Ф. К., Галиулин, Т. И., & Жумаев, О. А. (2018). АССОЦИАЦИЯ РИСКА РАЗВИТИЯ КАЗЕОЗНОЙ ПНЕВМОНИИ ПРИ ТУБЕРКУЛЕЗЕ ЛЕГКИХ С ГЕНЕТИЧЕСКИМИ МАРКЕРАМИ. Интернаука, (14-1), 52-53.
11.Вахабов, А. А., & Ташпулатова, Ф. К. (2018). Поражение печени у больных туберкулезом легких при побочных реакциях от противотуберкулезных препаратов. Молодой ученый, (3), 91-93.
12.
Хомова, Н. А., Коломиец, В. М., & Ташпулатова, Ф. К. (2020). Приверженность к лечению больных туберкулезом как фактор риска снижения его эффективности. In Университетская наука: взгляд в будущее (pp. 314-319).
13.
Tashpulatova, F., Shamshieva, N., Mukhteremova, V., Medvedeva, N., & Kurbanov, A. (2021). Phytotherapy in the Complex Treatment of Patients with Drug-Resistant Forms of Pulmonary Tuberculosis. Annals of the Romanian Society for Cell Biology, 25(1), 367-372.
14.
Ташпулатова, Ф. К., Жалолов, А. Ж., Медведева, Н. В., & Долгушева, Ю. В. (2016). Уровень комплаенса у больных с лекарственно устойчивым туберкулезом. In Медицина: вызовы сегодняшнего дня (pp. 46-50).
15.
Tashpulatova, F. K. (2003). Prevention of adverse reactions of antituberculous drugs in pulmonary tuberculosis in patients with different genetic background. Problemy tuberkuleza i boleznei legkikh, (6), 17-20.
16.Ташпулатова, Ф. К. (2017). Выявление туберкулеза легких в общесоматических лечебных учреждениях. Молодой ученый, (3), 236-238.
17.Ташпулатова, Ф. К., & Абдусаломова, М. И. (2020). Частота и характер побочных реакций от противотуберкулезных лекарственных средств у больных детей туберкулезом. Новый день в медицине, 2(30), 544-547.
18.Ташпулатова, Ф. К., & Абдусаломова, М. И. (2020). Частота и характер побочных реакций от противотуберкулезных лекарственных средств у больных детей туберкулезом. Новый день в медицине, 2(30), 544-547.
- Downloads
- Published
- 2026-02-11
- Issue
- Vol. 2 No. 2 (2026)
- Section
- Articles
- License
-
This work is licensed under a Creative Commons Attribution 4.0 International License.
